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TB is the leading cause of HIV/AIDS-related deaths globally. New diagnostic tools are urgently needed to avert
deaths from undiagnosed HIV-associated TB. Although simple assays that detect lipoarabinomannan (LAM) in
urine have been commercially available for years, their specific role and utility were initially misunderstood, such
that they have been slower to emerge from the diagnostics pipeline than otherwisemight have been expected. In
this article, we review and explain how urine-LAM assays should be understood as diagnostics for disseminated
TB in HIV-positive patients with advanced immunodeficiency, in whom haematogenous TB dissemination to the
kidneys serves as the primarymechanism bywhich LAM enters the urine. These insights are critical for the appro-
priate design of studies to evaluate these assays and to understand how theymight bemost usefully implemen-
ted. This understanding also supports the 2015 WHO recommendations on the restricted use of these assays in
sick HIV-positive patients with advanced immunodeficiency.
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Introduction
In this new era of the United Nations Sustainable Development
Goals (SDGs), the international community has committed to
ending the HIV/AIDS and TB epidemics by 2030.1 In 2014, the
World Health Assembly adopted the WHO’s post-2015 End TB
Strategy, with targets to assess progress using data from 2015
as the baseline.2 Goals to be achieved by 2030 include an 80%
reduction in new TB cases and a 90% reduction in TB deaths.
Furthermore, achieving an incidence of ,10 cases per 100 000
people per year was defined as being sufficient to ‘end’ the global
TB epidemic.
The remaining task, however, is huge.3 WHO reported that
in 2014 alone, 9.6 million people developed TB (12% HIV
co-infected) and 1.4 million died from TB disease (43% HIV
co-infected). Overall, TB remains the leading cause of HIV-related
deaths globally. A meta-analysis of hospital post-mortem studies
of HIV-related deaths included nine studies from across
sub-Saharan Africa.4 These found that between 32 and 67%
(pooled summary estimate, 43.2%; 95%CI 38.0–48.3) of
HIV-positive adult cadavers had evidence of TB at autopsy, and
that in over 90% of cases it was deemed the primary cause of
death.4 Disease was disseminated in 87.9% of TB cases, and
remained undiagnosed at death in nearly half of cases (45.8%).
These data highlight the critical need to improve the ascertain-
ment of disseminated HIV-associated TB. To achieve its ambitious
goals, the WHO End TB strategy has outlined the requirement for
‘intensified research and innovation’,1 including the development
and implementation of new, simple and accurate diagnostic
assays for TB.
For many years, the development of point-of-care assays has
been foremost on the TB research agenda. One such assay meth-
odology for TB diagnosis to emerge over the past 20 years has
been the detection of the mycobacterial cell well glycolipid anti-
gen lipoarabinomannan (LAM) in urine using immune-capture
assays. Much of the pioneering work on this was led by Prof.
Stefan Svenson at the Karolinska Institute in Sweden, who
demonstrated the proof of concept of urine-LAM detection as a
means for TB diagnosis.5 This early methodology required com-
plex sample processing, which was beyond the capacity of most
laboratories in high TB burden countries, and this was viewed as
an insurmountable obstacle to implementation. However, an
ELISA that required only minimal urine processing was developed
and marketed just over 10 years ago. The results of the first
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assessment of its diagnostic accuracy in Tanzania were very
encouraging,6 with high specificity among asymptomatic volun-
teers and high sensitivity in patients with laboratory-confirmed
pulmonary TB. Moreover, diagnostic accuracy was similar in
HIV-positive and HIV-negative patients. Had these findings been
replicated in larger studies in different settings, this assay would
have constituted a substantial breakthrough.
Optimism regarding this assay quickly evaporated, however, as
many subsequent studies reported poor diagnostic accuracy. A
meta-analysis in 20117 concluded these assays had “suboptimal
sensitivity for routine clinical use’ and many dismissed urine-LAM
detection as a viable diagnostic methodology. In retrospect,
many of the earlier studies targeted non-ideal patient groups
(HIV-negative patients or HIV-positive patients with high CD4
counts). However, progress came when the assay was applied
to HIV-positive adults with advanced immunodeficiency,8 in
whom specificity was high and sensitivity, although only moder-
ate at best, was highest among the sickest, most vulnerable
patients in whom slow culture-based diagnosis was otherwise
often required. The next breakthrough came with the develop-
ment of a 30-minute lateral-flow assay (strip-test) version of
the assay marketed as ‘Determine TB-LAM’ (Alere Inc. Waltham,
MA, USA). This assay format required neither laboratory infrastruc-
ture nor equipment, and was far lower cost per test than the Xpert
MTB/RIF assay (Cepheid, Sunnyvale, CA, USA). The results of the
ELISA and lateral flow assay formats were remarkably similar,
both showing markedly much greater sensitivity among those
patients with the lowest CD4 counts.9 Thus, urine LAM detection
emerged as ameans for rapid diagnosis of TB in people living with
HIV and advanced immunodeficiency.
Urine-LAM immune-capture assays have not been embraced
by the HIV and TB communities as fully or rapidly as one might
have expected. We propose that this is not only due to unfavour-
able data arising from earlier studies in which the assay was eval-
uated in inappropriate or non-ideal patient groups and using
sub-optimal study methodologies. We believe that, in addition
to these factors, the fundamental basis of the assays had not
been correctly understood—in particular, the mechanism by
which LAM enters urine. At first, this might seem an esoteric, aca-
demic issue, but we highlight why this issue is of fundamental
importance for the appropriate understanding and application
of these assays.
Early literature concerning urine-LAM assays presumed that
LAM-antigenuria resulted from simple renal filtration of free circu-
lating LAM in the bloodstream.6,10 This notion seemed plausible
since it was known that LAM was produced in large quantities
by Mycobacterium tuberculosis (MTB) at sites of disease from
which it could enter the blood-stream.11 Moreover, as a 17 kDa
glycolipid (similar in size to myoglobin) it should readily traverse
the renal glomerular basement membrane. Once produced
at sites of TB, whether pulmonary or extrapulmonary, it was
known that LAM was detectable in blood, albeit following exten-
sive sample processing in view of the high degree of immune-
complexing with host anti-LAM antibodies.12 Renal filtration of cir-
culating LAM also plausibly explained why the assay detected
both pulmonary and extrapulmonary forms of TB. However,
here we present a range of direct and indirect evidence that col-
lectively indicates that LAM antigenuria results from renal involve-
ment with TB and not from simple renal filtration of LAM from the
bloodstream into urine (Table 1).
Simple filtration of LAM at the renal glomerulus
is implausible
In addition to being immune-complexed within blood by anti-LAM
antibodies, LAM in the bloodstream is also incorporated within high
density lipoprotein (HDL) particles.13 Both immune-complexed or
HDL-associated LAM would be unable to pass from the systemic
circulation through the intact basement membrane in the renal
glomerulus.14 Whilst glomerular dysfunction might hypothetically
allow LAM-containing-complexes to pass into the urine, clinical
studies have not found associations between urine-LAM detection
and proteinuria (amarker for glomerular damage),15,16and there is
no histological evidence of glomerular damage at autopsy in
patients who were urine-LAM positive.17
LAM is released in large quantities by actively replicating or
dying mycobacteria, serving as an immune-modulating virulence
factor. If LAM were freely filtered into urine, it would be expected
that during early TB therapy when massive mycobacterial killing
occurs, urine concentrations of LAM would rise in parallel with
blood concentrations. However, the fact that urine-LAM levels
do not increase during early TB treatment is suggestive of amech-
anism other than simple renal filtration.15
Urine microbiology supports the renal TB
hypothesis (Table 1)
Urine culture has previously been shown to provide a high diag-
nostic yield in an American cohort of patients with AIDS and extra-
pulmonary TB inwhom77% tested urine-culture- positive.18 If the
presence of LAM in the urine of HIV-infected patients were the
result of renal TB, one would expect that M. tuberculosis would
be culturable from LAM-positive urine samples. However, data
correlating urine LAM status and urine culture status are unfortu-
nately lacking, at present. Nevertheless, other important evidence
comes from testing of urine samples with the Xpert MTB/RIF
assay. The Xpert MTB/RIF assay detects the presence of whole
MTB bacilli through amplification of organism-associated DNA
(rather than detection of free DNA).19,20 Studies testing the
urine of HIV-TB patients using TB-LAM and Xpert MTB/RIF have
shown a large overlap between the assays, with ≥50% of
LAM-positive urine samples also testing positive by Xpert MTB/
RIF.21–23 The detection of whole MTB bacilli in urine of these
LAM-positive patients strongly corroborates the notion of renal
TB as the source of urinary-LAM.
Evidence of renal TB from post-mortem studies
Renal TB in the form of microabscesses in this patient population
arises as a result of haematogenous dissemination and is a com-
mon autopsy finding in patients who have died fromdisseminated
HIV-associated TB (50–69%).24–27 In patients with advanced
HIV-infection (typically CD4 cell counts of ,100 cells/mm3)
a strong association between MTB bacteraemia and urine
LAM-positivity has been observed, with 70–90% of bacteraemic
patients also having detectable LAM-antigenuria.28–31 Renal TB
readily provides a mechanism for this association.
The strongest evidence explaining the mechanism of urine
LAM-antigenuria is provided by post-mortem studies. Cox et al.
demonstrated histological evidence of renal TB in the majority
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of deceased patients with LAM detected in their urine.17 All
LAM-positive patients had evidence of either renal or dissemi-
nated TB. Renal TB is also frequently found in cadavers of adults
with disseminated TB at post-mortem, typically being seen in
more than 50% of such cases.24–27
That LAM-antigenuria is due to renal involvement with haema-
togenously disseminated TB rather than filtration of LAM also
explains several observations about urine-LAM assays, with impli-
cations for future research.
What are the implications?
Thus far, we have presented evidence supporting the notion that
LAM-antigenuria results from renal involvement with TB arising
from haematogenous TB dissemination and not from simple
renal filtration of circulating LAM. This understanding is critical
as it provides many important insights into the urine-LAM assays
and their particular niche within the TB diagnostics armamentar-
ium. Here we now discuss the implications of this knowledge
(Tables 2 and 3).
Renal TB explains why urine-LAM assays only
have utility in HIV-infected patients
Diagnostic accuracy studies have found the utility of urine-LAM
assays to be almost entirely restricted to HIV-positive adults
with advanced immunodeficiency.7 Disseminated TB, and
therefore renal TB, are comparatively much less common among
immune-competent patients. Furthermore, assay sensitivity is
very strongly associated with low CD4 cell counts, being highest
among those with CD4 counts ,50 cells/mL,7,32 the very patient
group with highest risks of mycobacteraemia and disseminated
and renal TB. Thus, understanding the mechanism of LAM-
antigenuria directly explains why urine LAM-assays have utility
restricted to a defined patient group and why the earlier diagnostic
accuracy studies focusing on other patient groups generated largely
unfavourable data. The results of studies of urine-LAM assays were
also disappointing in children with no useful diagnostic accuracy
observed, which is likely to be explained by the paucibacillary nature
of paediatric TB, contrasting with the overwhelming multi-bacillary
nature of disseminated TB in adults with advanced HIV.4,33
Higher mortality in urine-LAM positive patients
Several studies have now demonstrated that HIV-TB co-infected
patients who test urine-LAM-positive have much poorer prognos-
tic characteristics and higher mortality risk compared to cases
testing LAM-negative.28,34–36 This increased mortality risk persists
even after adjustment for important risk factors such as CD4 cell
count and anaemia.35,37,38 The fact that urine LAM-positivity
serves as a marker of disseminated/renal TB, is an entirely plaus-
ible reason for this association with prognosis, as HIV-TB patients
with mycobacteraemia are known to have highmortality risk.39,40
Diagnosing mycobacteraemia by liquid culture of blood samples
can take 2 to 6 weeks, and is largely unavailable outside research
Table 1. Direct and indirect evidence that urine lipoarabinomannan (LAM) antigenuria is due to renal involvement with haematogenously
disseminated TB, and not free filtration of LAM into the urine
Observation Evidence References
LAM is unlikely to be able to pass from
systemic circulation into the urine via the
renal glomerulus
† LAM in the bloodstream is mostly immune-complexed or bound
to high-density lipoprotein
† These LAM containing molecules are too large to freely filter in
the renal glomerulus
Sada et al. 199212
Sakamuri et al. 201313
Haraldsson et al. 200814
LAM concentration in the urine does not
increase during the first weeks of TB
treatment
† Serum LAM concentration likely increases early after the massive
mycobactericidal effect of anti-TB treatment.
Wood et al. 201215
† If LAMwas freely filtered in the kidneys, LAM concentration in the
urine would also be expected to increase early after treatment
Bekker et al. 199845
Most LAM-positive urines test XpertMTB/
RIF-positive
† Xpert MTB/RIF detects M. tuberculosis DNA in whole bacilli (not
free DNA), suggesting most LAM-positive urines contain whole
M. tuberculosis bacilli
Wood et al. 201215
Lawn et al. 201221
Blakemore et al. 201019
Frequent LAM-positive urine in patients with
M. tuberculosis bacteraemia
† The strong association between M. tuberculosis bacteraemia and
LAM-positive urine is very plausibly linked mechanistically by
haematogenously disseminated renal TB
Manabe et al. 201428
Nakiyingi et al. 201529
Nakiyingi et al. 201430
Lawn & Kerkhoff 201531
In patients with disseminated TB at autopsy,
renal TB is common
† Prevalence of renal TB is similar to the sensitivity of LAM-positive
urine in this population
Lanjewar et al. 201125
Ansari et al. 200224
Cox et al. 201517
Post-mortem renal TB in HV-positive patients
is associated with LAM-positive urine
† A Ugandan Autopsy study revealed frequent renal TB in those
whose urine also tested LAM-positive and all LAM-positive
patients had haematogenously disseminated TB
† No patients with renal TB were urine LAM-negative
Cox et al. 201517
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facilities inmost high burden settings. However, urine-LAM testing
can quickly (a 30 min test) identify 80%of patients withmycobac-
teraemia,31 therefore expediting the diagnosis of MTB bacter-
aemia among patients with high mortality risk. Further research
is required to see if interventions in addition to expediting TB treat-
ment can reduce this very high mortality risk.
Underestimation of urine-LAM specificity due
to an inadequate reference standard for
disseminated TB in diagnostic accuracy studies
Finally, understanding that urine LAM-positivity represents dissemi-
nated and renal TB helps to explain why assessments of Determine
Table 2. Observations about urine lipoarabinomannan (LAM) assays explained by LAM-antigenuria resulting from renal involvement with TB
Observation Evidence References
The utility of the assay is almost entirely restricted to
testing adult patients who are HIV-infected.
† Haematogenously disseminated TB, and therefore
renal TB, is rare amongst immune-competent patients
† If LAM were freely filtered sensitivity amongst
pulmonary TB cases should be higher
Minion et al. 20117
Assay sensitivity is very strongly associated with blood
CD4 cell count, (highest among CD4 counts,50 cells/
mL and lowest among CD4 counts .200 cells/mL).
† Haematogenously disseminated TB, and therefore
renal TB, is more common with more advanced
immunosuppression in HIV
Lawn et al. 20098
Lawn et al. 20129
Minion et al. 20117
The assay has no utility among children † Paediatric TB is usually paucibacillary with rare
dissemination of TB disease, even in the context of HIV
Nicol M et al. 201433
Urine LAM assays should not be specifically targeted to
the investigation of HIV-positive patients with
respiratory symptoms of TB
† Diagnostic yield of LAM is unrelated to respiratory
symptoms (cough or sputum production)
Lawn et al. 201423
LAM-antigenuria is a strong independent predictor of
mortality among patients with HIV-associated TB.
† Renal and haematogenously disseminated TB is
associated with greater mycobacterial burden, which is
likely to adversely impact prognosis
Lawn et al. 201435
Talbot et al. 201237
Drain et al. 201538
Studies of urine-LAM find much higher specificity when
the reference standard for TB diagnosis includes
testing of extra-pulmonary samples in addition to
sputum
Testing extra-pulmonary samples increases the chances
that disseminated TB is correctly detected, and fewer
urine-LAM positive patients will be misclassified as ‘not
TB’ due to inadequate reference standards.
Cox et al. 201517
Lawn et al. 201435
Nakiyingi et al. 201430
Table 3. Implications of lipoarabinomannan (LAM) antigenuria being a consequence of disseminated renal
Issue Implications References
Targeting the assay to appropriate patient
groups
† LAM assays should be prioritised for testing sick HIV-positive adults,
such as those requiring acute hospital admission rather than
ambulatory out-patients
† Interpretation of urine-LAM results requires knowledge of HIV status
† There are no data showing utility for testing in children
Nakiyingi et al. 201430
Design of diagnostic accuracy studies † The reference standard for disseminated TB requires testing more
than one specimen type, a single sputum culture is inadequate
† Ideally this would includemycobacterial blood cultures and/or urine
Xpert MTB/RIF assay testing
Lawn et al. 201541
Design of studies to assess incremental
diagnostic yield of urine-LAM testing
† Should include patients bothwith andwithout respiratory symptoms Lawn et al. 201446
Studies of clinical impact of Urine-LAM
testing
† Studies should focus on acute HIV-positive medical admissions in
whom undiagnosed TB and mycobacteraemia is common. e.g.
LAMRCT and STAMP trials42,43
Gupta et al. 20154
Lawn & Kerkhoff 201531
Patients testing LAM-positive have poorer
prognosis than those testing
LAM-negative
† Patients testing urine-LAM-positive are much sicker and have poorer
prognostic characteristics compared with those with TB who testing
LAM-negative
Manabe et al. 201428
Lawn et al. 201336
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TB-LAM specificity are sub-optimal in many studies in which refer-
ence standard testing for TB was restricted to a single respiratory
sample.41 LAM-positive disseminated and renal TBmay be very eas-
ily missed by such a reference standard, especially among very sick
patients unable to produce good quality sputum samples and
would, therefore, be inappropriately misclassified as ‘TB-free’.
Specificity of urine LAM-detection is ≥99% when the reference
standard includes comprehensive extra-pulmonary sampling that
is much more likely to detect disseminated TB and thereby accur-
ately classifies patients as having TB or being TB-free.17,23,41
Conclusion
Theadvent of a simple ELISA-based format for urine-LAMdetection
for TB diagnosis was greeted with much optimism in 2005, and yet
many were perplexed by the results of subsequent studies, which
were designed based on a limited understanding of these assays,
including the mechanism of LAM-antigenuria, which has profound
implications. In effect, the advent of urine-LAM assays heralded
the development of simple assays for rapid diagnosis of dissemi-
nated HIV-associated TB with renal involvement, providing
not only rapid diagnosis but also key prognostic information. This
emerging understanding has now culminated in randomised trials
of urine-based diagnosis to determine whether their addition
to routine diagnostic screening algorithms averts deaths from
HIV-associated TB by improving and accelerating the TB diagnostic
yield.42,43 Results of such studies are awaited.
This paper highlights the critical importance that new diagnostic
assays are thoroughly understood mechanistically and are applied
to the most appropriate patient groups. Without this, there is a risk
that some of the output of the TB diagnostics developmental pipe-
line might potentially be squandered. However, the mechanistic
framework for understanding the utility of the urine LAM assays
that we have described in this article is strongly supportive of the
WHO recommendations regarding the use of these assays for diag-
nosis. These specifically restrict or target the use in HIV-positive
patients who have the highest risk of disseminated TB (notably
in-patients who are sick and have CD4 cell counts,100 cells/mL).44
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